AssetMark Inc’s Editas Medicine EDIT Stock Holding History

AssetMark Inc’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$380	Buy	+148	New	+$434	﹤0.01%	3479

Other funds holding EDIT

Cambridge Investment Research Advisors Fairfield, Iowa $45.2B AUM 20.72% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return

Thrive Wealth Management Audubon, Pennsylvania $805M AUM 17.78% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.67B AUM 22.25% 1-Year Est. Return

AssetMark Inc's EDIT Position: Q3 2026 in Review

AssetMark Inc opened a new position in Editas Medicine (EDIT) in Q3 2026: 148 shares worth $380. The stake represents ﹤0.01% of the portfolio and ranks #3479 among its holdings.

66 funds tracked by Wall St. Rank hold EDIT as of Q3 2026.

AssetMark Inc held 148 shares of Editas Medicine worth $380 as of Q3 2026.
Editas Medicine was a new AssetMark Inc position in Q3 2026.
Editas Medicine made up ﹤0.01% of AssetMark Inc's portfolio in Q3 2026, its #3479 holding.
66 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.